In recent years, GLP-1 receptor agonists first developed as diabetes medications exploded in popularity after researchers discovered they could also dramatically improve weight loss
BPC-157 Synthetic Pentadecapeptide BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide composed of 15 amino acids
MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID
It is used solely as a research tool for exploring peptide-driven signalling mechanisms in vitro, and no conclusions about biological effects in humans or animals should be drawn from this work
